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Objectives: This study aims to investigate the relationship of hemoglobin level with disease
activity in patients with rheumatoid arthritis (RA).
Patients and methods: The hemoglobin level, the 66/68 joint count, the Disease Activity Score
28  joints (DAS28), the Health Assessment Questionnaire (HAQ), the Visual Analog Scales
(VAS), the Modiﬁed Sharp Score (MSS), and the disease duration in 89 patients with RA were
used  to analyze the possible relationship. The World Health Organization (WHO) criteria for
anemia uses a hemoglobin threshold of < 120 g/L for women and < 130 g/L for men. Pregnant
or  breastfeeding patients, patients with a history of other inﬂammatory or no inﬂammatory
arthritis, malignancies, chronic infectious and inﬂammatory diseases and other diseases in
the  stage of decompensation were excluded from the study.
Results: Anemia was observed in 64% of the patients (1st group); the other group (2nd group)
had normal levels of hemoglobin. There was a statistically signiﬁcant negative correlation
between hemoglobin level and swollen and tender joints’ count, DAS28, HAQ score, VAS,
MSS, and disease duration (p < 0.001). DAS28, HAQ score, VAS, MSS, swollen and tender joints’
count and disease duration were signiﬁcantly (p < 0.001) higher in 1st versus 2nd group.
Conclusion: In conclusion, we determined that low hemoglobin level was signiﬁcantly related
to  disability and impairment, disease activity, articular damage, pain and disease duration in
RA  patients in our study. We believe that by keeping disease activity under control, therefore
preventing articular damage, the disability in RA patients can be lessened or possibly even
eliminated.
©  2014 Elsevier Editora Ltda. All rights reserved.
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Anemia
Atividade da doenc¸a
Pacientes e métodos: Avaliou-se a possível relac¸ão existente entre o nível de hemoglobina, a
contagem de 66/68 articulac¸ões, o Escore de Atividade da Doenc¸a – 28 articulac¸ões (DAS28), o
Questionário de Avaliac¸ão de Saúde (HAQ), a escala visual analógica (EVA), o Escore de Sharp
modiﬁcado (MSS) e a durac¸ão da doenc¸a de 89 pacientes com AR. Os critérios para anemia da
Organizac¸ão  Mundial de Saúde (OMS) consideram um limite de hemoglobina < 120 g/L para
as  mulheres e < 130 g/L para os homens. Pacientes grávidas ou amamentando, pacientes
com história de outra artrite inﬂamatória ou não inﬂamatória, neoplasias, doenc¸as crônicas
infecciosas e inﬂamatórias e outras doenc¸as descompensadas foram excluídas do estudo.
Resultados: A anemia foi observada em 64% dos pacientes (1◦ grupo); o outro grupo (2◦
grupo) apresentou níveis normais de hemoglobina. Houve uma correlac¸ão negativa estatis-
ticamente signiﬁcativa entre o nível de hemoglobina e a contagem de articulac¸ões inchadas
e  sensíveis, DAS28, HAQ, EVA, MSS e durac¸ão da doenc¸a (p < 0,001). O DAS28, escore HAQ,
EVA,  MSS, contagem de articulac¸ões inchadas e sensíveis e durac¸ão da doenc¸a foram signi-
ﬁcativamente maiores (p < 0,001) no primeiro grupo em comparac¸ão com o segundo.
Conclusão: Determinou-se que o baixo nível de hemoglobina está signiﬁcativamente correla-
cionado com a deﬁciência e incapacidade, atividade da doenc¸a, lesão articular, dor e durac¸ão
da  doenc¸a em pacientes com AR. Acredita-se que, mantendo a atividade da doenc¸a sob
controle, evitando danos articulares será possível diminuir ou, possivelmente, até mesmo
eliminar a incapacidade em pacientes com AR.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Rheumatoid arthritis (RA) is a chronic systemic inﬂammatory
disorder characterized by inﬂammation in the synovium of
joints, malaise, morning stiffness and fatigue.1,2 It is asso-
ciated with progressive joint destruction and, depending on
the severity, may be accompanied by systemic manifesta-
tion including effects on the blood.3 In particular, anemic
syndrome is a very common manifestation of rheumatoid
inﬂammation that could increase RA activity and decrease
patient’s quality of life.4 Unfortunately, anemia is not consid-
ered a major problem in rheumatoid arthritis RA by the vast
majority of physicians. This statement is based on the fact that
studies on anemia in RA are sparse, with few systemic reviews,
and no extensive literature on its prevalence and effect on
various clinical and functional outcomes, including morbidity,
mortality, and quality of life. Some results suggest that anemia
is associated with a negative impact on both RA symptoms and
quality of life. Thus the question needs to be raised of why
so little research on anemia-related outcomes has been con-
ducted. This gap in the literature is strange because anemia is
a common comorbidity in patients with RA. Additional large-
scale studies on prevalence and anemia-related outcomes are
needed to support the importance of anemia screening and
treatment in RA.
Thus, the aim of our study was to investigate the relation-
ship between hemoglobin level and disease activity in patients
with rheumatoid arthritis (RA) by using the 66/68 joint count,
the DAS 28, the HAQ, the VAS, the MSS,  and duration of disease.
Patients  and  methodsThe study was comprised of 89 Ukrainian patients (females;
mean age 51.7 ± 10.3 years) who  were diagnosed with RAaccording to the American College of Rheumatology (ACR)
classiﬁcation criteria,5 and written informed consent was
obtained from all of the participants. The patients were
assigned to one of two groups on the basis of their
hemoglobin concentration. The ﬁrst group was composed of
57 female patients who fulﬁlled the criteria for anemia. The
World Health Organization (WHO) criteria for anemia use a
hemoglobin threshold of < 120 g/L for women, and < 130 g/L
for men. The second group was made up of 32 non-anemic
female patients. The 66/68 joint count, the DAS 28 joints, the
HAQ, the VAS, the MSS and disease duration of each group
were used to analyze the possible relationship. Pregnant or
breastfeeding patients, patients with a history of other inﬂam-
matory or non-inﬂammatory arthritis, malignancies, chronic
infectious and inﬂammatory diseases and other diseases in
the stage of decompensation were excluded from the study.
The local ethics committee of the National Medical University
in Donetsk, Ukraine, gave their approval.
Blood samples were collected using the Sarstedt tube sys-
tem (Sarstedt Inc., Nümbrecht, Germany). The blood count
was then measured electronically by the ABX Micros ES 60
hemotology analyzer (Horiba ABX SAS, Montpelier, France).
The 66/68 joint count includes the metacarpophalangeal,
proximal interphalangeal and distal interphalangeal joints of
the hands, the metatarsal phalangeal and distal interpha-
langeal joints of the feet and the shoulder, elbow, wrist, hip,
knee, ankle, tarsus, and temporomandibular, sternoclavicular
and acromioclavicular joints.
Disease activity was determined with the DAS 28
and calculated using the following equation: DAS
28 = 0.56 ×√(tender 28 joint count) + 0.28 ×√(swollen
28 joint count) + 0.70 × ln(erythrocyte sedimentation rate
(ESR), mm/hr) + 0.014 × general health.6 General health is
subject global assessment using a 100 mm VAS.
The level of disability was investigated using the HAQ,7
which consists of 20 questions in eight subcategories: dressing
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Table 1 – Comparison of the RA activity of the two groups.
Parameters P-values 1st Group
(57 patients)
2nd Group
(32 patients)
Duration of RA, years 0.004 11.62 ± 3.54 7.63 ± 3.48
Swollen joint 0.002 28.67 ± 9.01 16.53 ± 8.27
Tender joint 0.001 31.42 ± 10.07 18.52 ± 11.28
DAS28 0.001 5.2 ± 1.3 2.8 ± 1.1
HAQ 0.02 1.4 ± 0.6 1.98 ± 0.55
VAS (pain assessment), mm 0.004 68.11 ± 12.34 37.17 ± 9.48
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and higher DAS 28, and by faster hemoglobin normalization
after TNF- blockade. Anemia in RA may be caused by a
shortened red blood cell lifespan, pathologic iron homeostasis
Table 2 – The results of a correlation analysis between
the hemoglobin level and the clinical parameters of RA
activity.
Laboratory test Correlation
coefﬁcient (r)
P-values
Duration of RA, years -0.62 p < 0.001
Swollen joint -0.61 p < 0.001
Tender joint -0.59 p < 0.001
DAS 28 -0.57 p < 0.001
HAQ -0.48 p < 0.001
VAS (pain assessment), mm -0.52 p < 0.001VAS (global assessment of disease activity), mm 0.004
MMS 0.001
nd grooming, arising, eating, walking, hygiene, reach, grip,
nd common daily activities. Responses in each functional
rea are scored from 0 (without any difﬁculty) to 3 (unable to
o). The highest score recorded for any question in a category
s the score for that category, unless aids, devices, or help from
nother person is required. Dependence on aids or devices or
elp from others results in a minimum category score of 2.
he HAQ score is calculated as the sum of the category scores
ivided by the number of categories scored, giving a possible
ange of scores from 0 to 3.
Patients were asked to assess their average pain during the
ast week on a VAS (0 to 100 mm).  The scale ranges from 0 (no
ain) to 100 (severe pain). Patients were also asked to assess
heir disease progression on a VAS (0 to 100 mm).  They marked
n a VAS their overall assessment of how their RA has affected
hem, rating how they are managing from 0 (very well) to 100
very poorly). The VAS scores were measured in millimeters.8
The MSS  was used in our study to evaluate structural artic-
lar damage via plain X-rays taken of both hands and feet.9
he erosion score per each joint of the hands ranges from 0
o 5, and, per each joint of the feet, ranges from 0 to 10. The
aximum total erosion score for two hands is 160, the highest
arrowing score is 120, and the maximum MSS score is 280.
he maximum total erosion score for feet is 120, the highest
arrowing score is 48, and the maximum MSS  score is 168. The
aximum total score for one patient is 448.
Statistical analyses were performed using the MEDSTAT
ersion 4.0 for Windows software program (The MEDSTAT
roup, Inc., Ann Arbor, MI). The Shapiro-Wilk normality test
as employed to assess whether or not the data was nor-
ally distributed and descriptive data was presented as
ean ± standard deviation (SD) because the data was dis-
ributed normally. Correlations between hemoglobin level and
wollen and tender joint count, the DAS28, HAQ score, VAS,
SS, and disease duration were investigated with Spearman’s
ank correlation test. A P-value of less than 0.05 was consid-
red to be statistically signiﬁcant.
esults
nemia was observed in 57 (64%) of the patients (1st group).
he others (2nd group) had normal levels of hemoglobin
135.5 ± 10.7 g/l). The patients from the 1st and 2nd groups
ere statistically similar with regard to age (p = 0.21). The clin-
cal parameters of the patients are shown in Table 1. The DAS
8, HAQ score, VAS, MSS,  swollen and tender joint count, dis-
ase duration were signiﬁcantly (p < 0.001) higher in 1st group71.21 ± 15.42 44.56 ± 11.41
235.37 ± 24.82 137.54 ± 19.61
compared to the 2nd. The results of a correlation analysis
between the hemoglobin level and the clinical parameters of
RA activity are shown in Table 2. There were statistically sig-
niﬁcant negative correlations between the hemoglobin level
and the swollen and tender joint, DAS 28, HAQ, MSS,  VAS, and
disease duration (p < 0.001).
Discussion
We  found that duration and activity of RA were signiﬁcantly
(p < 0.05) higher in patients with anemia compared to patients
with normal hemoglobin level. In 2009, Furst et al.10 reported
that anemic syndrome in RA patients could be a marker of
high activity and severity of disease. Similarly, Borah et al.11
reported that RA activity, according to the DAS 28 and HAQ
score, was signiﬁcantly higher in patients with anemia com-
pared to patients with normal hemoglobin level (6.85 ± 0.64;
1.41 ± 0.44 and 4.76 ± 1.29; 0.7 ± 0.25, respectively; p < 0.05).
Results of other studies have shown that patients with low
hemoglobin level had higher number of affected joints than
patients without anemia.12 Similar to the current literature,
we found negative correlation between the hemoglobin level
and the swollen/tender joint, DAS 28, HAQ, MSS,  VAS, and
disease duration.
The well established relationship between inﬂammation
and anemia was conﬁrmed in different studies by signiﬁ-
cant associations between lower hemoglobin concentrationsVAS (global assessment of
disease activity), mm
-0.59 p < 0.001
MMS -0.61 p < 0.001
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induced by hepcidin, and blunted response to erythropoietin.
Cytokines also have a direct toxic effect on erythropoietin. Kul-
lich et al.13 found that TNF- level was signiﬁcantly higher in
RA patients who had anemia, than in those without it. Simi-
larly, Zhu et al. reported that patients suffering from RA and
anemia had increased TNF- level and decreased serum eryth-
ropoietin concentration. This allowed the authors to suggest
that TNF inhibits the production of erythropoietin. Interest-
ingly, erythropoietin treatment reduced disease activity in
RA patients and tissue damage in collagen-induced arthritis
models. Hepcidin may trigger functional iron deﬁciency upon
induction by TNF-, interleukin-6, resulting in reduced intesti-
nal iron uptake at the mucosal barrier, and iron retention in
the reticule-endothelial system via internalization of the same
exclusive cellular iron exporter ferroportin on both cell types.
Corticosteroids may carry an increased risk of anemia due to
toxic mucosal drug effects or a bias by indication.
In summary, these results indicate that anemia may serve
as predictor of worse outcome in RA patients. Our data suggest
that anemia is associated independently of common disease
activity outcome measures. This report may add clinical back-
ground to recent discoveries at the nexus of inﬂammation,
hematopoiesis and iron metabolism, and highlights the clin-
ical implications of anemia in RA. Diagnosis of anemia in RA
should prompt a thorough search for subclinical disease activ-
ity, after exclusion of other frequent causes.
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